In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni raise over $170M in new funding, achieve regulatory clearances, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Appointed Colonel John R. Dorsch, DO (ret), as Medical Director of Trauma Therapies, effective December 2, 2024. With ample experience in military operational medicine and emergency care, Colonel Dorsch will play a critical role in advancing Amsel Medical’s trauma care innovations, including its SCureTO development projects.
Appointed Dr. Amanda Williams to its Board of Directors to strengthen leadership in maternal health monitoring. Dr. Williams brings extensive experience in women’s health innovation and strategic growth, positioning Bloomlife to advance its maternal care technologies.
Closed a $50M oversubscribed growth funding round to scale its wearable neuromodulation therapies. The investment will support the expansion of Cala Health’s innovative treatments for chronic disease management, such as its Cala TAPS (Transcutaneous Afferent Patterned Stimulation) Therapy for essential tremor.
Secured $110M in an oversubscribed Series C funding round to advance its robotic heart disease treatment platform. This investment will accelerate the development of Capstan’s minimally invasive solutions for structural heart disease, aiming to improve patient outcomes and recovery times.
Received IDE approval from the FDA for its Flexible Robotic System. This clearance enables EndoQuest to initiate its pivotal colorectal clinical study, marking a significant step toward offering less invasive surgical options.
Earned FDA TAP Pilot Acceptance and Breakthrough Device Designation for its FieldForce Ablation System. The system is designed to treat ventricular tachycardia through advanced ablation technology, potentially improving outcomes for patients with this life-threatening arrhythmia.
Enrolled the first patient in the CGuardians II study of its CGuard Prime Carotid Stent System. This pivotal trial evaluates the device’s performance in transcarotid artery revascularization (TCAR), aiming to enhance stroke prevention strategies.
Received FDA 510(k) clearance for its Versus Catheter, designed to enhance the treatment of pulmonary artery blood clots. This regulatory milestone paves the way for the product’s U.S. market launch, offering new options for vascular interventions.
Raised $2.5M in additional funding to advance its cancer-care product portfolio. The funds will support the development and commercialization of innovative solutions aimed at improving the quality of life for cancer patients.
Announced a new clinical trial of its Monarch eTNS System for pediatric ADHD at Denmark’s Center for Evidence-Based Psychiatry. The study will evaluate the therapy’s effectiveness in treating children with ADHD, potentially offering a non-pharmacological treatment option.
Secured €6.5M in a Series A investment round led by EQT Life Sciences. The funds will be allocated toward the manufacturing, testing, regulatory approval, and initial commercialization of the company’s product, the SteriCISION C-Section Retractor.
Received over £1M in NIHR i4i PDA grant funding to enhance its robotics and AI platform for neurosurgery. The funds will fuel product development and clinical validation efforts, advancing precision in neurosurgical procedures.
Presented research demonstrating that its Histolog Scanner reduced reoperation rates in breast-conserving surgery by 67%. The device also achieved a sensitivity of 80.9% and a specificity of 99.5% for positive margin detection, compared to the combined sensitivity of 17.4% and specificity of 97.3% seen with conventional methods.
Appointed Jeff Eardley as its new Chief Commercial Officer, bringing extensive medtech leadership experience. Eardley will guide the company’s next phase of growth in sterile processing innovation, aiming to enhance operational efficiencies in healthcare facilities.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
